Neurocrine Biosciences, Inc. (NBIX) Q2 2023 Earnings Results

Neurocrine Biosciences Beats on EPS, Stock Up 1.52%

Neurocrine Biosciences reported a strong EPS performance, exceeding expectations significantly. The stock reacted positively, rising by 1.52%. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.25	N/A	+61.92%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. They acknowledged the need to stay vigilant regarding market dynamics.

We are pleased with our EPS performance this quarter.

Our focus remains on advancing our pipeline.

We continue to monitor market conditions closely.

Neurocrine Biosciences Beats on EPS, Stock Up 1.52%

Key numbers

Management commentary

Neurocrine Biosciences, Inc.

More earnings this week

Neurocrine Biosciences Beats on EPS, Stock Up 1.52%

Key numbers

Management commentary